An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus Nicotine Replacement Therapy. Issue 1 (2nd January 2017)

• Record Type: Journal Article
• Authors: Balfour, Louise; Wiebe, Stephanie A.; Cameron, William D.; Sandre, Daniella; Pipe, Andrew; Cooper, Curtis; Angel, Jonathan; Garber, Gary; Holly, Crystal; Dalgleish, Tracy L.; Tasca, Giorgio A.; MacPherson, Paul A.
• Is Part Of: AIDS care. Volume 29:Issue 1(2017)
• Page Start: 24
• Page End: 31
• Publication Date: 2017-01-02
• Subjects: Smoking cessation -- HIV/AIDS -- cardiovascular disease -- depression; AIDS (Disease) -- Social aspects -- Periodicals; AIDS (Disease) -- Psychological aspects -- Periodicals; AIDS (Disease) -- Patients -- Care -- Periodicals; Acquired Immunodeficiency Syndrome; 362.1969792
• DOI: 10.1080/09540121.2016.1201195
• Languages: English
• ISSNs: 0954-0121

Abstract

ABSTRACT: Cardiovascular disease (CVD) rates among people living with HIV/AIDS (PHAs) are high. Rates of cigarette smoking, a leading contributor to CVD among PHAs, are 40–70% (2–3 times higher than the general population). Furthermore, PHAs have high rates of depression (40–60%), a risk factor for smoking cessation relapse. The current pilot study examined the effectiveness of a specifically tailored 5-session smoking cessation counselling programme for PHAs, which addressed depression, in combination with Nicotine Replacement Therapy (NRT) in a cohort of PHA smokers ( n = 50). At 6-month follow-up, 28% of participants demonstrated biochemically verified abstinence from smoking. This result compares favourably to other quit-smoking intervention studies, particularly given the high percentage of HIV+ smokers with depression. At study baseline, 52% of HIV+ smokers scored above the clinical cut-off for depression on the Centre for Epidemiological Studies – Depression (CES-D) scale. HIV+ smokers with depression at study baseline demonstrated quantitatively lower depression at 6-month follow-up with a large effect size ( d = 1), though it did not reach statistical significance ( p = .058). Furthermore, those with depression were no more likely to relapse than those without depression ( p = .33), suggesting that our counselling programme adequately addressed this significant barrier to smoking cessation among PHAs. Our pilot study indicates the importance of tailored programmes to help PHAs quit smoking, the significance of addressing depressive symptoms, and the need for tailored counselling programmes to enhance quit rates among PHAs.